New TB drugs offer cautious hope | Institut Pasteur de Tunis-معهد باستور تونس | Scoop.it

Tuberculosis is a disease of the poor: today, 95% of global cases occur in low- and middle-income countries. Without a profit incentive, the impetus for companies to make new drugs is small, leaving patients and doctors with few good treatment options.

But with the rise of multidrug-resistant (MDR) TB, which has a mortality rate of nearly 80% and is about 100 times more expensive to treat than “ordinary” TB, new treatments are needed more than ever.


Via BTC